Inhaled corticosteroids (ICS) are the most effective controllers of asthma. They suppress inflammation mainly by switching off multiple activated inflammatory genes through reversing histone acetylation via the recruitment of histone deacetylase 2 (HDAC2). Through suppression of airway inflammation ICS reduce airway hyperresponsiveness and control asthma symptoms. ICS are now first-line therapy for all patients with persistent asthma, controlling asthma symptoms and preventing exacerbations. Inhaled long-acting β 2-agonists added to ICS further improve asthma control and are commonly given as combination inhalers, which improve compliance and control asthma at lower doses of corticosteroids. By contrast, ICS provide much less clinical benefit in COPD and the inflammation is resistant to the action of corticosteroids. This appears to be due to a reduction in HDAC2 activity and expression as a result of oxidative stress. ICS are added to bronchodilators in patients with severe COPD to reduce exacerbations. ICS, which are absorbed from the lungs into the systemic circulation, have negligible systemic side effects at the doses most patients require, although the high doses used in COPD has some systemic side effects and increases the risk of developing pneumonia.
References
[1]
Barnes, P.J. How corticosteroids control inflammation. Br. J. Pharmacol.？2006, 148, 245–254.
[2]
Rhen, T.; Cidlowski, J.A. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. New Engl. J. Med.？2005, 353, 1711–1723.
Gibson, P.G.; Saltos, N.; Fakes, K. Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am. J. Respir. Crit. Care Med.？2001, 163, 32–36.
[5]
Ketchell, R.I.; Jensen, M.W.; Lumley, P.; Wright, A.M.; Allenby, M.I.; O'Connor, B.J. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5'-monophosphate in mild asthma. J. Allergy Clin. Immunol.？2002, 110, 603–606.
[6]
Erin, E.M.; Zacharasiewicz, A.S.; Nicholson, G.C.; Tan, A.J.; Neighbour, H.; Engelstatter, R.; Hellwig, M.; Minn, K.O.; Barnes, P.J.; Hansel, T.T. Rapid anti-inflammatory effect of inhaled ciclesonide in asthma: a randomised, placebo-controlled study. Chest？, 2008, doi:10.1378/chest.07-2575.
[7]
Juniper, E.F.; Kline, P.A.; Yan Zieleshem, M.A.; Ramsdale, E.H.; O'Byrne, P.M.; Hargreave, F.E. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur. Respir. J.？1990, 3, 1122–1127.
[8]
Lewis-Tuffin, L.J.; Cidlowski, J.A. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann. NY Acad. Sci.？2006, 1069:1-9, 1–9, doi:10.1196/annals.1351.001.
[9]
Pujols, L.; Mullol, J.; Picado, C. Alpha and beta glucocorticoid receptors: relevance in airway diseases. Curr. Allergy Asthma Rep.？2007, 7, 93–99.
Clark, A.R.; Martins, J.R.; Tchen, C.R. Role of dual specificity phosphatases in biological responses to glucocorticoids. J. Biol.Chem.？2008, 283, 25765–25769.
[12]
Dostert, A.; Heinzel, T. Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr. Pharm. Des.？2004, 10, 2807–2816.
[13]
Barnes, P.J.; Adcock, I.M.; Ito, K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respi. J.？2005, 25, 552–563.
[14]
Hart, L.; Lim, S.; Adcock, I.; Barnes, P.J.; Chung, K.F. Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor-kB in asthma. Am. J. Respir. Crit. Care Med.？2000, 161, 224–231.
[15]
Ito, K.; Barnes, P.J.; Adcock, I.M. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits IL-1b-induced histone H4 acetylation on lysines 8 and 12. Mol. Cell Biol.？2000, 20, 6891–6903.
[16]
Bergmann, M.W.; Staples, K.J.; Smith, S.J.; Barnes, P.J.; Newton, R. Glucocorticoid inhibition of GM-CSF from T cells is independent of control by NF-kB and CLE0. Am. J. Respir. Cell. Mol. Biol.？2004, 30, 555–563. 14527927
[17]
Brook, M.; Tchen, C.R.; Santalucia, T.; McIlrath, J.; Arthur, J.S.; Saklatvala, J.; Clark, A.R. Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways. Mol. Cell Biol.？2006, 26, 2408–2418.
[18]
Thomson, N.C.; Spears, M. The influence of smoking on the treatment response in patients with asthma. Curr. Opin. Allergy Clin. Immunol.？2005, 5, 57–63.
Ito, K.; Ito, M.; Elliott, W.M.; Cosio, B.; Caramori, G.; Kon, O.M.; Barczyk, A.; Hayashi, M.; Adcock, I.M.; Hogg, J.C.; Barnes, P.J. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. New Engl. J. Med.？2005, 352, 1967–1976.
[21]
Hew, M.; Bhavsar, P.; Torrego, A.; Meah, S.; Khorasani, N.; Barnes, P.J.; Adcock, I.; Chung, K.F. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am. J. Respir. Crit. Care Med.？2006, 174, 134–141.
[22]
Barnes, P.J. Role of HDAC2 in the pathophysiology of COPD. Ann. Rev. Physiol.？2009, 71, 451–464.
[23]
Irusen, E.; Matthews, J.G.; Takahashi, A.; Barnes, P.J.; Chung, K.F.; Adcock, I.M. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: Role in steroid-insensitive asthma. J. Allergy Clin. Immunol.？2002, 109, 649–657.
[24]
Matthews, J.G.; Ito, K.; Barnes, P.J.; Adcock, I.M. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J. Allergy Clin. Immunol.？2004, 113, 1100–1108.
[25]
Barnes, P.J. Scientific rationale for combination inhalers with a long-acting b2-agonists and corticosteroids. Eur. Respir. J.？2002, 19, 182–191.
[26]
Mak, J.C.W.; Nishikawa, M.; Barnes, P.J. Glucocorticosteroids increase b2-adrenergic receptor transcription in human lung. Am. J. Physiol.？1995, 12, L41–L46.
[27]
Baraniuk, J.N.; Ali, M.; Brody, D.; Maniscalco, J.; Gaumond, E.; Fitzgerald, T.; Wonk, G.; Mak, J.C.W.; Bascom, R.; Barnes, P.J.; Troost, T. Glucocorticoids induce b2-adrenergic receptor function in human nasal mucosa. Am. J. Respir. Crit. Care Med.？1997, 155, 704–710.
[28]
Mak, J.C.W.; Nishikawa, M.; Shirasaki, H.; Miyayasu, K.; Barnes, P.J. Protective effects of a glucocorticoid on down-regulation of pulmonary b2-adrenergic receptors in vivo. J. Clin. Invest.？1995, 96, 99–106, doi:10.1172/JCI118084. 7615841
[29]
Mak, J.C.; Chuang, T.T.; Harris, C.A.; Barnes, P.J. Increased expression of G protein-coupled receptor kinases in cystic fibrosis lung. Eur. J. Pharmacol.？2002, 436, 165–172.
[30]
Roth, M.; Johnson, P.R.; Rudiger, J.J.; King, G.G.; Ge, Q.; Burgess, J.K.; Anderson, G.; Tamm, M.; Black, J.L. Interaction between glucocorticoids and b2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet？2002, 360, 1293–1299.
[31]
Usmani, O.S.; Ito, K.; Maneechotesuwan, K.; Ito, M.; Johnson, M.; Barnes, P.J.; Adcock, I.M. Glucocorticoid receptor nuclear translocation in airway cells following inhaled combination therapy. Am. J. Respir. Crit Care Med.？2005, 172, 704–712.
[32]
Barnes, P.J.; Pedersen, S.; Busse, W.W. Efficacy and safety of inhaled corticosteroids: an update. Am. J. Respir. Crit Care Med.？1998, 157, S1–S53.
[33]
Lipworth, B.J. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis [see comments]. Arch.Intern.Med.？1999, 159, 941–955.
[34]
Derendorf, H.; Hochhaus, G.; Meibohm, B.; Mollmann, H.; Barth, J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J. Allergy Clin. Immunol.？1998, 101, S440–S446.
[35]
Brown, P.H.; Greening, A.P.; Crompton, G.K. Large volume spacer devices and the influence of high dose beclomethasone diproprionate on hypothalamo-pituitary-adrenal axis function. Thorax？1993, 48, 233–238.
[36]
Derendorf, H. Corticosteroid pharmacokinetic/pharmacodynamic parameters and their relationship to safety and efficacy. Allergy Asthma Proc.？2005, 26, 327–335.
[37]
Derendorf, H. Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. J. Clin.Pharmacol.？2007, 47, 782–789.
Suissa, S.; Barnes, P.J. Inhaled corticosteroids in COPD: the case against. Eur. Respir. J.？2009, 34, 13–16.
[40]
Haahtela, T.; Jarvinen, M.; Kava, T.; Kiviranta, K.; Koskinen, S.; Lehtonen, K.; Nivander, K.; Persson, T.; Reinikainen, R.; Selroos, O.; Sovijarvi, A.; Stenius-Aarniala, B.; Svahn, T.; Tammivaara, R.; Laitinen, L.A. Comparison of a b2-agonist terbutaline with an inhaled steroid in newly detected asthma. New Engl. J. Med.？1991, 325, 388–392.
[41]
Juniper, E.F.; Kline, P.A.; Vanzieleghem, M.A.; Ramsdale, E.H.; O'Byrne, P.M.; Hargreave, F.E. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am. Rev. Respir. Dis.？1990, 142, 832–836.
[42]
Pauwels, R.A.; Pedersen, S.; Busse, W.W.; Tan, W.C.; Chen, Y.Z.; Ohlsson, S.V.; Ullman, A.; Lamm, C.J.; O'Byrne, P.M. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet？2003, 361, 1071–1076.
[43]
Mash, B.; Bheekie, A.; Jones, P.W. Inhaled vs. oral steroids for adults with chronic asthma. Cochrane Database. Syst. Rev.？2000, 2, CD002160. 10796683
[44]
Jatakanon, A.; Lim, S.; Barnes, P.J. Changes in sputum eosinophils predict loss of asthma control. Am. J. Respir. Crit. Care Med.？2000, 161, 64–72.
[45]
Leuppi, J.D.; Salome, C.M.; Jenkins, C.R.; Anderson, S.D.; Xuan, W.; Marks, G.B.; Koskela, H.; Brannan, J.D.; Freed, R.; Andersson, M.; Chan, H.K.; Woolcock, A.J. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am. J. Respir. Crit Care Med.？2001, 163, 406–412.
[46]
Berger, W.E. Budesonide inhalation suspension for the treatment of asthma in infants and children. Drugs？2005, 65, 1973–1989.
[47]
Busse, W.W.; Chervinsky, P.; Condemi, J.; Lumry, W.R.; Petty, T.L.; Rennard, S.; Townley, R.G. Budesonide delivered by Turbuhaler is effective in a dose- dependent fashion when used in the treatment of adult patients with chronic asthma. J. Allergy Clin. Immunol.？1998, 101, 457–463.
[48]
Adams, N.P.; Jones, P.W. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respir. Med.？2006, 100, 1297–1306.
[49]
Pauwels, R.A.; Lofdahl, C.-G.; Postma, D.S.; Tattersfield, A.E.; O'Byrne, P.M.; Barnes, P.J.; Ullman, A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. New Engl. J. Med.？1997, 337, 1412–1418.
[50]
Lim, S.; Jatakanon, A.; John, M.; Gilbey, T.; O'Connor, B.J.; Chung, K.F.; Barnes, P.J. Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. Am. J. Respir. Crit. Care Med.？1999, 159, 22–30. 9872813
[51]
Jatakanon, A.; Lim, S.; Chung, K.F.; Barnes, P.J. An inhaled steroid improves markers of inflammation in asymptomatic steroid-naive asthmatic patients. Eur. Respir. J.？1998, 12, 1084–1088.
[52]
Jatakanon, A.; Kharitonov, S.; Lim, S.; Barnes, P.J. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax？1999, 54, 108–114.
[53]
Kharitonov, S.A.; Donnelly, L.E.; Montuschi, P.; Corradi, M.; Collins, J.V.; Barnes, P.J. Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax？2002, 57, 889–896.
[54]
Sont, J.K.; Willems, L.N.; Bel, E.H.; van Krieken, J.H.; Vandenbroucke, J.P.; Sterk, P.J. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long- term treatment. The AMPUL Study Group. Am. J. Respir. Crit. Care Med.？1999, 159, 1043–1051. 10194144
Smith, A.D.; Cowan, J.O.; Brassett, K.P.; Herbison, G.P.; Taylor, D.R. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. New Engl. J. Med.？2005, 352, 2163–2173.
[58]
Dompeling, E.; Van Schayck, C.P.; Molema, J.; Folgering, H.; van Grusven, P.M.; van Weel, C. Inhaled beclomethasone improves the course of asthma and COPD. Eur. Resp. J.？1992, 5, 945–952.
[59]
O'Byrne, P.M.; Pedersen, S.; Busse, W.W.; Tan, W.C.; Chen, Y.Z.; Ohlsson, S.V.; Ullman, A.; Lamm, C.J.; Pauwels, R.A. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest？2006, 129, 1478–1485.
[60]
Lange, P.; Scharling, H.; Ulrik, C.S.; Vestbo, J. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax？2006, 61, 100–104.
[61]
Haahtela, T.; J？rvinsen, M.; Kava, T.; Kiviranta, K.; Koskinen, S.; Lemtonen, K.; Nikander, K.; Person, T.; Selroos, O.; Sovij？ri, A.; Stenius-Aarniala, B.; Svahn, T.; Tammivaara, R.; Laitinen, L.A. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. New Engl. J. Med.？1994, 331, 700–705.
[62]
Agertoft, L.; Pedersen, S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Resp. Med.？1994, 5, 369–372.
[63]
Selroos, O.; Pietinalcho, A.; Lofroos, A.-B.; Riska, A. Effect of early and late intervention with inhaled corticosteroids in asthma. Chest？1995, 108, 1228–1234.
[64]
Suissa, S.; Ernst, P.; Benayoun, S.; Baltzan, M.; Cai, B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N. Engl. J. Med.？2000, 343, 332–336.
[65]
Ernst, P.; Habbick, B.; Suissa, S.; Hemmelgarn, B.; Cockcroft, D.; Buist, A.S.; Horwitz, R.I.; McNutt, M.; Spitzer, W.O. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? Am. Rev.Respir. Dis.？1993, 148, 75–79. 8100409
[66]
Nelson, H.S.; Weiss, S.T.; Bleecker, E.R.; Yancey, S.W.; Dorinsky, P.M. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest？2006, 129, 15–26.
[67]
Weatherall, M.; Wijesinghe, M.; Perrin, K.; Harwood, M.; Beasley, R. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax？2010, 65, 39–43.
[68]
Kelly, H.W. Comparison of inhaled corticosteroids: an update. Ann. Pharmacother.？2009, 43, 519–527.
[69]
Nathan, R.A.; Nayak, A.S.; Graft, D.F.; Lawrence, M.; Picone, F.J.; Ahmed, T.; Wolfe, J.; Vanderwalker, M.L.; Nolop, K.B.; Harrison, J.E. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann. Allergy Asthma Immunol.？2001, 86, 203–210.
Malo, J.-L.; Cartier, A.; Merland, N.; Ghezzo, H.; Burke, A.; Morris, J.; Jennings, B.H. Four-times-a-day dosing frequency is better than twice-a-day regimen in subjects requiring a high-dose inhaled steroid, budesonide, to control moderate to severe asthma. Am. Rev. Respir. Dis.？1989, 140, 624–628. 2551204
[72]
Otulana, B.A.; Varma, N.; Bullock, A.; Higenbottam, T. High dose nebulized steroid in the treatment of chronic steroid-dependent asthma. Resp. Med.？1992, 86, 105–108.
Rabe, K.F.; Hurd, S.; Anzueto, A.; Barnes, P.J.; Buist, S.A.; Calverley, P.; Fukuchi, Y.; Jenkins, C.; Rodriguez-Roisin, R.; van Weel, C.; Zielinski, J. Global strategy for the diagnosis, management, and prevention of COPD - 2006 Update. Am. J. Respir. Crit. Care Med.？2007, 176, 532–555.
Calverley, P.M.; Anderson, J.A.; Celli, B.; Ferguson, G.T.; Jenkins, C.; Jones, P.W.; Yates, J.C.; Vestbo, J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med.？2007, 356, 775–789.
[77]
Kankaanranta, H.; Lahdensuo, A.; Moilanen, E.; Barnes, P.J. Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. Respir. Res.？2004, 5, 17.
[78]
Greening, A.P.; Ind, P.W.; Northfield, M.; Shaw, G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet？1994, 344, 219–224.
[79]
Shrewsbury, S.; Pyke, S.; Britton, M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ？2000, 320, 1368–1373.
[80]
O'Byrne, P.M.; Barnes, P.J.; Rodriguez-Roisin, R.; Runnerstrom, E.; Sandstrom, T.; Svensson, K.; Tattersfield, A. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am. J. Respir. Crit Care Med.？2001, 164, 1392–1397.
[81]
Gibson, P.G.; Powell, H.; Ducharme, F.M. Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J. Allergy Clin. Immunol.？2007, 119, 344–350.
[82]
Ni, C.M.; Greenstone, I.R.; Ducharme, F.M. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. Cochrane Database Syst. Rev.？2005, CD005307.
[83]
O'Byrne, P.M.; Bisgaard, H.; Godard, P.P.; Pistolesi, M.; Palmqvist, M.; Zhu, Y.; Ekstrom, T.; Bateman, E.D. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am. J. Resp. Crit. Care Med.？2005, 171, 129–136.
[84]
Rabe, K.F.; Pizzichini, E.; Stallberg, B.; Romero, S.; Balanzat, A.M.; Atienza, T.; Lier, P.A.; Jorup, C. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest？2006, 129, 246–256.
[85]
Rabe, K.F.; Atienza, T.; Magyar, P.; Larsson, P.; Jorup, C.; Lalloo, U.G. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet？2006, 368, 744–753.
[86]
Tattersfield, A.E.; Postma, D.S.; Barnes, P.J.; Svensson, K.; Bauer, C.A.; O'Byrne, P.M.; Lofdahl, C.G.; Pauwels, R.A.; Ullman, A. Exacerbations of asthma. A descriptive study of 425 severe exacerbations. Am. J. Respir. Crit. Care Med.？1999, 160, 594–599. 10430734
[87]
Barnes, P.J. New therapies for asthma. Trends Mol. Med.？2006, 12, 515–520.
[88]
Calverley, P.; Pauwels, R.; Vestbo, J.; Jones, P.; Pride, N.; Gulsvik, A.; Anderson, J. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomoised controlled trial. Lancet？2003, 361, 449–456.
[89]
Szafranski, W.; Cukier, A.; Ramirez, A.; Menga, G.; Sansores, R.; Nahabedian, S.; Peterson, S.; Olsson, H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J.？2003, 21, 74–81.
[90]
Nannini, L.; Cates, C.; Lasserson, T.; Poole, P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.？2007, CD006829.
[91]
Wedzicha, J.A.; Calverley, P.M.; Seemungal, T.A.; Hagan, G.; Ansari, Z.; Stockley, R.A. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med.？2008, 177, 19–26.
[92]
Evans, D.J.; Taylor, D.A.; Zetterstrom, O.; Chung, K.F.; O'Connor, B.J.; Barnes, P.J. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. New Engl. J. Med.？1997, 337, 1412–1418.
[93]
Ukena, D.; Harnest, U.; Sakalauskas, R.; Magyar, P.; Vetter, N.; Steffen, H.; Leichtl, S.; Rathgeb, F.; Keller, A.; Steinijans, V.W. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur. Respir. J.？1997, 10, 2754–2760.
[94]
Lim, S.; Jatakanon, A.; Gordon, D.; Macdonald, C.; Chung, K.F.; Barnes, P.J. Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax？2000, 55, 837–841, doi:10.1136/thorax.55.10.837. 10992535
[95]
Wilson, A.J.; Gibson, P.G.; Coughlan, J. Long acting beta-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst. Rev.？2000, CD001281.
[96]
Laviolette, M.; Malmstrom, K.; Lu, S.; Chervinsky, P.; Pujet, J.C.; Peszek, I.; Zhang, J.; Reiss, T.F. Montelukast added to inhaled beclomethasone in treatment of asthma. Am. J. Respir. Crit. Care Med.？1999, 160, 1862–1868.
[97]
Price, D.B.; Hernandez, D.; Magyar, P.; Fiterman, J.; Beeh, K.M.; James, I.G.; Konstantopoulos, S.; Rojas, R.; van Noord, J.A.; Pons, M.; Gilles, L.; Leff, J.A. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax？2003, 58, 211–216.
[98]
Nelson, H.S.; Busse, W.W.; Kerwin, E.; Church, N.; Emmett, A.; Rickard, K.; Knobil, K. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J. Allergy Clin. Immunol.？2000, 106, 1088–1095.
[99]
Ducharme, F.; Schwartz, Z.; Hicks, G.; Kakuma, R. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Databas. Syst. Rev.？2004, CD003133.
[100]
Ducharme, F.M.; Lasserson, T.J.; Cates, C.J. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst. Rev.？2006, CD003137.
[101]
Williamson, I.J.; Matusiewicz, S.P.; Brown, P.H.; Greening, A.P.; Crompton, G.K. Frequency of voice problems and cough in patients using pressurised aersosol inhaled steroid preparations. Eur. Resp. J.？1995, 8, 590–592.
[102]
Toogood, J.A.; Jennings, B.; Greenway, R.W.; Chung, L. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J. Allergy Clin. Immunol.？1980, 65, 145–153.
[103]
Ernst, P.; Gonzalez, A.V.; Brassard, P.; Suissa, S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am. J. Respir. Crit. Care Med.？2007, 176, 162–166.
[104]
Sin, D.D.; Tashkin, D.; Zhang, X.; Radner, F.; Sjobring, U.; Thoren, A.; Calverley, P.M.; Rennard, S.I. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet？2009, 374, 712–719.
[105]
Kamada, A.K.; Szefler, S.J.; Martin, R.J.; Boushey, H.A.; Chinchilli, V.M.; Drazen, J.M.; Fish, J.E.; Israel, E.; Lazarus, S.C.; Lemanske, R.F. Issues in the use of inhaled steroids. Am. J. Respir. Crit Care Med.？1996, 153, 1739–1748.
[106]
Brutsche, M.H.; Brutsche, I.C.; Munawar, M.; Langley, S.J.; Masterson, C.M.; Daley-Yates, P.T.; Brown, R.; Custovic, A.; Woodcock, A. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet？2000, 356, 556–561.
[107]
Harrison, T.W.; Wisniewski, A.; Honour, J.; Tattersfield, A.E. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax？2001, 56, 186–191.
[108]
Efthimou, J.; Barnes, P.J. Effect of inhaled corticosteroids on bone and growth. Eur. Respir. J.？1998, 11, 1167–1177.
[109]
Roy, A.; Leblanc, C.; Paquette, L.; Ghezzo, H.; Cote, J.; Cartier, A.; Malo, J.-L. Skin bruising in asthmatic subjects treated with high does of inhaled steroids: frequency and association with adrenal function. Eur. Respir. J.？1996, 9, 226–231.
[110]
Simons, F.E.R.; Persaud, M.P.; Gillespie, C.A.; Cheang, M.; Shuckett, E.P. Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet？1993, 342, 736–738.
[111]
Garbe, E.; LeLorier, J.; Boivin, J.-F.; Suissa, S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angel glaucoma. JAMA？1997, 227, 722–727.
[112]
Pedersen, S. Do inhaled corticosteroids inhibit growth in children? Am. J. Respir. Crit. Care Med.？2001, 164, 521–535. 11520710
[113]
Allen, D.B.; Mullen, M.; Mullen, B. A meta-analysis of the effects of oral and inhaled corticosteroids on growth. J. Allergy Clin. Immunol.？1994, 93, 967–976.
[114]
Silverstein, M.D.; Yunginger, J.W.; Reed, C.E.; Petterson, T.; Zimmerman, D.; Li, J.T.; O'Fallon, W.M. Attained adult height after childhood asthma: effect of glucocorticoid therapy. J. Allergy Clin. Immunol.？1997, 99, 466–474.
[115]
Agertoft, L.; Pedersen, S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. New Engl. J. Med.？2000, 343, 1064–1069.
[116]
Schatz, M. Asthma and pregnancy. Lancet？1999, 353, 1202–1204.
[117]
Ernst, P.; Baltzan, M.; Deschenes, J.; Suissa, S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur. Respir. J.？2006, 27, 1168–1174.
